Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Cancer of Unknown Primary (CUPem)
NCT03752333Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Feb 2019
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cancer of unknown primary (CUP), sponsored by Imperial College London. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT03752333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752333.